For Gilead, PrEP seems to be the future focus. Here is an article summarizing the Ccr5 potential in PrEP. Just in that area alone, you would think Gilead would be very interested in Sacha’s data. If leronlimab works with PrEP monotherapy as well, it could take a large chunk out of Gilead’s revenue. A few years from now this could be another yahoo moment, turning down then unknown google, just to become dominated years later. I said that on iHub a couple years ago and a few people laughed, more are starting to see that possibility now. Gilead has kept delaying, kept delaying, well now it looks like they have less than 6 weeks to decide, and some major sources of revenue could be lost to them if they don’t act now and are wrong. The FDA’s letter has to be concerning for them.


https://smw.ch/article/doi/smw.2018.14580/
Preventing HIV transmission through blockade of CCR5: rationale, progress and perspectives

CCR5: a key player in the infection of target cells by HIV